NasdaqGS:ALNYBiotechs
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Tenaya Cardiovascular Partnership
Tenaya partnership broadens Alnylam’s reach into cardiovascular research
The new collaboration between Alnylam Pharmaceuticals (ALNY) and Tenaya Therapeutics gives Alnylam access to up to 15 cardiovascular gene targets. Tenaya will handle early validation, while Alnylam will fund and lead downstream drug development.
Tenaya is set to receive up to US$10 million upfront plus cost reimbursement over a two-year validation period. The company may also earn as much as US$1.13 billion in...